ADM Tronics Reports Second Quarter of Fiscal Year 2025 Results
Rhea-AI Summary
ADM Tronics (OTCQB:ADMT) reported financial results for Q2 FY2025. Revenues increased 12% to $1,697,881 for the six months ended September 30, 2024, compared to $1,516,821 in the same period last year. The company posted income from operations of $118,423 versus a loss of $365,446 in the prior year period. For Q2, revenues grew 11% to $840,036, though operating loss was $45,858 compared to a $228,105 loss last year. The improvement was driven by increased revenues in engineering and chemical segments. The company continues R&D on its proprietary non-invasive musculoskeletal pain therapy device, planning an FDA 510(k) submission.
Positive
- Revenue growth of 12% year-over-year for six months ended September 30, 2024
- Turned operating loss into profit for six-month period ($118,423 vs -$365,446)
- Significant improvement in gross profit ($939,685 vs $531,294)
- Net income of $219,481 for six months vs loss of $360,366 last year
Negative
- Q2 operating loss of $45,858
- Reduced revenues in electronics segment during Q2
- Increased operating expenses in Q2 ($464,640 vs $433,802)
News Market Reaction 1 Alert
On the day this news was published, ADMT declined 0.13%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
NORTHVALE, NJ / ACCESSWIRE / November 14, 2024 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies and products, announces results for its second fiscal quarter ended September 30, 2024 of Fiscal Year 2025.
The upward trend in revenues, as reported in the Company's last quarterly report, continues for this second fiscal quarter of fiscal year ended March 31, 2025 with an increase in revenues of
Revenues for the six months ended September 30, 2024 were
Revenues for the three months ended September 30, 2024 were
Complete financial results are available in the Company's Quarterly Report on Form 10Q for September 30, 2024, available at www.sec.gov.
Financial Highlights
| Three Months Ended |
|
| Six Months Ended |
| |||||||||||
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 |
| |||||
Net revenues |
| $ | 840,036 |
|
| $ | 754,132 |
|
| $ | 1,697,881 |
|
| $ | 1,516,821 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Cost of sales |
| $ | 421,254 |
|
| $ | 547,980 |
|
| $ | 758,196 |
|
| $ | 985,527 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Gross Profit |
| $ | 418,782 |
|
| $ | 206,152 |
|
| $ | 939,685 |
|
| $ | 531,294 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Total Operating expenses |
| $ | 464,640 |
|
| $ | 433,802 |
|
| $ | 821,262 |
|
| $ | 896,740 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Income (loss) from operations |
| $ | (45,858 | ) |
| $ | (227,650 | ) |
| $ | 118,423 |
|
| $ | (365,446 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Total other income (expense) |
| $ | (6,329 | ) |
| $ | (455 | ) |
| $ | 102,058 |
|
| $ | 5,080 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Net income (loss) |
| $ | (52,687 | ) |
| $ | (228,105 | ) |
| $ | 219,481 |
|
| $ | (360,366 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Basic and diluted per common share |
| $ | (0.00 | ) |
| $ | (0.00 | ) |
| $ | 0.00 |
|
| $ | (0.01 | ) |
Weighted average shares of common stock outstanding - basic and diluted |
|
| 67,588,492 |
|
|
| 67,588,492 |
|
|
| 67,588,492 |
|
|
| 67,588,492 |
|
About ADMT
ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Safe, Water-Based Formulations. The Company's headquarters, laboratories, FDA-Registered medical device and manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for the research, development and commercialization of diversified technologies. Additional information is available at admtronics.com
Sign up for ADMT Investor News Updates emails by filling in the form at the bottom of the page at this link: https://admtronics.com/investor-relations/
ADMT welcomes inquiries for its electronics and medical device contract engineering and manufacturing services at www.admteng.com.
Investor Relations:
Howard Isaacs 562-987-4939 HISAACS@EARTHLINK.NET
Richard Cavalli 303-956-1777 RICHARDACAVALLI@GMAIL.COM
Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.
View the original press release on accesswire.com
FAQ
What was ADMT's revenue growth in Q2 FY2025?
How much profit did ADMT report for the six months ended September 30, 2024?
What is ADMT's current development focus in medical devices?
